233 related articles for article (PubMed ID: 31527069)
1. Blockade of β-Adrenergic Receptors Improves CD8
Daher C; Vimeux L; Stoeva R; Peranzoni E; Bismuth G; Wieduwild E; Lucas B; Donnadieu E; Bercovici N; Trautmann A; Feuillet V
Cancer Immunol Res; 2019 Nov; 7(11):1849-1863. PubMed ID: 31527069
[TBL] [Abstract][Full Text] [Related]
2. Chronic Adrenergic Stress Contributes to Metabolic Dysfunction and an Exhausted Phenotype in T Cells in the Tumor Microenvironment.
Qiao G; Chen M; Mohammadpour H; MacDonald CR; Bucsek MJ; Hylander BL; Barbi JJ; Repasky EA
Cancer Immunol Res; 2021 Jun; 9(6):651-664. PubMed ID: 33762351
[TBL] [Abstract][Full Text] [Related]
3. β-Adrenergic signaling blocks murine CD8
Qiao G; Bucsek MJ; Winder NM; Chen M; Giridharan T; Olejniczak SH; Hylander BL; Repasky EA
Cancer Immunol Immunother; 2019 Jan; 68(1):11-22. PubMed ID: 30229289
[TBL] [Abstract][Full Text] [Related]
4. β-Adrenergic Signaling Impairs Antitumor CD8
Nissen MD; Sloan EK; Mattarollo SR
Cancer Immunol Res; 2018 Jan; 6(1):98-109. PubMed ID: 29146881
[TBL] [Abstract][Full Text] [Related]
5. Leveraging β-Adrenergic Receptor Signaling Blockade for Improved Cancer Immunotherapy Through Biomimetic Nanovaccine.
Yang C; He Y; Chen F; Zhang F; Shao D; Wang Z
Small; 2023 Apr; 19(14):e2207029. PubMed ID: 36703529
[TBL] [Abstract][Full Text] [Related]
6. Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine.
Lutz-Nicoladoni C; Wallner S; Stoitzner P; Pircher M; Gruber T; Wolf AM; Gastl G; Penninger JM; Baier G; Wolf D
Immunol Cell Biol; 2012 Jan; 90(1):130-4. PubMed ID: 21383769
[TBL] [Abstract][Full Text] [Related]
7. Dissecting the role of cell signaling versus CD8
Li W; Wan J; Chen C; Zhou C; Liao P; Hu Q; Hu J; Wang Y; Zhang Y; Peng C; Huang Y; Huang W; Zhang W; Mcleod HL; He Y
J Mol Med (Berl); 2022 Sep; 100(9):1299-1306. PubMed ID: 35895125
[TBL] [Abstract][Full Text] [Related]
8. β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8
Bucsek MJ; Qiao G; MacDonald CR; Giridharan T; Evans L; Niedzwecki B; Liu H; Kokolus KM; Eng JW; Messmer MN; Attwood K; Abrams SI; Hylander BL; Repasky EA
Cancer Res; 2017 Oct; 77(20):5639-5651. PubMed ID: 28819022
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
[TBL] [Abstract][Full Text] [Related]
10. CD40 ligand promotes priming of fully potent antitumor CD4(+) T cells in draining lymph nodes in the presence of apoptotic tumor cells.
Fujita N; Kagamu H; Yoshizawa H; Itoh K; Kuriyama H; Matsumoto N; Ishiguro T; Tanaka J; Suzuki E; Hamada H; Gejyo F
J Immunol; 2001 Nov; 167(10):5678-88. PubMed ID: 11698440
[TBL] [Abstract][Full Text] [Related]
11. Propranolol Suppresses the Growth of Colorectal Cancer Through Simultaneously Activating Autologous CD8
Liao P; Song K; Zhu Z; Liu Z; Zhang W; Li W; Hu J; Hu Q; Chen C; Chen B; McLeod HL; Pei H; Chen L; He Y
Clin Pharmacol Ther; 2020 Sep; 108(3):606-615. PubMed ID: 32418204
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
[TBL] [Abstract][Full Text] [Related]
13. Immune-Checkpoint Blockade Opposes CD8
Pfannenstiel LW; Diaz-Montero CM; Tian YF; Scharpf J; Ko JS; Gastman BR
Cancer Immunol Res; 2019 Mar; 7(3):510-525. PubMed ID: 30728151
[TBL] [Abstract][Full Text] [Related]
14. Administration of 6-gingerol greatly enhances the number of tumor-infiltrating lymphocytes in murine tumors.
Ju SA; Park SM; Lee YS; Bae JH; Yu R; An WG; Suh JH; Kim BS
Int J Cancer; 2012 Jun; 130(11):2618-28. PubMed ID: 21792901
[TBL] [Abstract][Full Text] [Related]
15. Magnetic targeting of adoptively transferred tumour-specific nanoparticle-loaded CD8
Sanz-Ortega L; Portilla Y; Pérez-Yagüe S; Barber DF
J Nanobiotechnology; 2019 Aug; 17(1):87. PubMed ID: 31387604
[TBL] [Abstract][Full Text] [Related]
16. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
[TBL] [Abstract][Full Text] [Related]
17. Treatment-enhanced CD4+Foxp3+ glucocorticoid-induced TNF receptor family related high regulatory tumor-infiltrating T cells limit the effectiveness of cytokine-based immunotherapy.
Berhanu A; Huang J; Watkins SC; Okada H; Storkus WJ
J Immunol; 2007 Mar; 178(6):3400-8. PubMed ID: 17339434
[TBL] [Abstract][Full Text] [Related]
18. Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression.
Wang Y; Sun SN; Liu Q; Yu YY; Guo J; Wang K; Xing BC; Zheng QF; Campa MJ; Patz EF; Li SY; He YW
Cancer Discov; 2016 Sep; 6(9):1022-35. PubMed ID: 27297552
[TBL] [Abstract][Full Text] [Related]
19. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
Zhang X; Niedermann G
Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
[TBL] [Abstract][Full Text] [Related]
20. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
